On Thursday shares of JPMorgan Chase & Co. (NYSE:JPM) closed at $66.05. Company’s sales growth for last 5 years was -4.90% and EPS growth for next 5 years is recorded as 7.65%. JPMorgan Chase & Co. (NYSE:JPM) is buying roughly $45 billion worth of home loans from Atlanta-based Ocwen Financial Corporation.
Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA) in last trading activity increased 1.95% to close at $9.92. Company weekly performance is 1.85% while its quarterly performance stands at -19.81%. Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA) is -39.88% away from its 52 week high. Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA) announced that Mihael H. Polymeropoulos, M.D., Vanda’s President and CEO, delivered a corporate presentation at the Bank of America Merrill Lynch 2015 Health Care Conference in Las Vegas, Nevada on Wednesday, May 13, 2015 at 2:20 p.m. Pacific Time.
On last trading day Thermo Fisher Scientific, Inc. (NYSE:TMO) increased 0.96% to close at $131.10. Its volatility for the week is 1.06% while volatility for the month is 1.30%. TMO’s sales growth for past 5 years was 11.20% and its EPS growth for past 5 years was 19.30%. Thermo Fisher Scientific, Inc. (NYSE:TMO) monthly performance is -1.89%. Thermo Fisher Scientific, Inc. (NYSE:TMO) Introduces Two New Printers for Pathologists. The Thermo Scientific SlideMate AS on-demand slide printer offers laboratories an accurate, easy-to-use, integrated solution for printing microscope slides. The SlideMate features a space-saving design that integrates the functionality of an external PC, label-creation software, barcode scanner and printer in a small, clutter-free footprint. Its compact, five-by-nine-inch form factor makes it an ideal labeling solution for laboratories where space is at a premium.
Vipshop Holdings Limited (NYSE:VIPS) has 3.61% insider ownership while its institutional ownership stands at 78.10%. In last trading activity company’s stock closed at $25.21. Vipshop Holdings Limited (NYSE:VIPS) issued a light guidance for the second quarter. Vipshop said it expects to report revenue of RMB 8.7 billion to RMB 8.9 billion for the second quarter, or about $1.4 billion to $1.43 billion. Analysts surveyed by Thomson Reuters expect the company to report revenue of $1.45 billion for the second quarter.
On Thursday shares of Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) closed at $20.42. Company’s EPS growth for next 5 years is recorded as 5.10%. Biopharmaceutical company Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) announced that Chief Financial Officer Mark Fitzpatrick has resigned. The company has named Chief Accounting Officer David Aubuchon to serve as acting CFO in the interim.